MYOS (NASDAQ:MYOS) will release its earnings data after the market closes on Tuesday, November 13th. Analysts expect MYOS to post earnings of ($0.14) per share for the quarter.
MYOS (NASDAQ:MYOS) last announced its quarterly earnings data on Wednesday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). MYOS had a negative return on equity of 101.86% and a negative net margin of 883.55%. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.20 million. On average, analysts expect MYOS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ:MYOS traded up $0.01 during midday trading on Wednesday, hitting $1.29. The stock had a trading volume of 300 shares, compared to its average volume of 31,134. MYOS has a one year low of $1.03 and a one year high of $2.50. The stock has a market cap of $8.09 million, a P/E ratio of -1.87 and a beta of 1.17.
Separately, ValuEngine raised MYOS from a “hold” rating to a “buy” rating in a research note on Friday, October 12th.
ILLEGAL ACTIVITY NOTICE: “MYOS (MYOS) Set to Announce Earnings on Tuesday” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/07/myos-myos-set-to-announce-earnings-on-tuesday.html.
MYOS Company Profile
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Read More: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.